New Horizons in the Treatment and Management of Endometrial Cancer: Leveraging Immunotherapy for Improved Clinical and Economic Outcomes
 
 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2024 to March 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
GlaxoSmithKline

Description:
Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States. The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age. There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. Fortunately for patients with endometrial cancer, new and emerging therapies, including immune based therapies such as PD-1 Inhibitors, having recently been approved, giving managed care professionals and clinicians more options for treating this patient population. With so many new therapies entering the treatment paradigm knowledge gaps have been created, making imperative that managed care physician medical directors, oncologists, pharmacists, payers, nurses and other healthcare professionals who manage EC patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of endometrial cancer (EC), including factors that contribute to poor prognosis and increased costs

  • Recognize the role of biomarker expression in the selection of most appropriate treatment options for patients with endometrial cancer

  • Cite the rationales, therapeutic roles, and key efficacy/safety evidence supporting the use of immuno-oncology treatments for patients with recurrent or advanced endometrial cancer

  • Analyze the guideline-recommended role of PD-1 inhibitors in the management of endometrial cancer

  • Identify managed care directed strategies to improve access to medication and overcome treatment disparities in endometrial cancer

  • Implement cost of care and utilization management strategies to optimize the use of PD-1 inhibitors in the treatment of endometrial cancer
     

Faculty:
Dario R. Roque, MD
Assistant Professor, Gynecologic Oncology
Gynecologic Oncology Fellowship Program Director
Department of Obstetrics & Gynecology
Feinberg School of Medicine at Northwestern University

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Roque has served on the speaker's bureau for GlaxoSmithKline and Myriad. He has served on an advisory board for GlaxoSmithKline and Myriad. He has served as a consultant for Intuitive. All relevant conflicts of interest have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

This activity is supported by an educational grant from
GlaxoSmithKline


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue